On Demand 2017 Which T2 Biologic is Best Suited for GINA 4-5 Non-responders? (MOC)

Price: NOW 20% OFF! $20 members, $28 non-members

You can earn up to 1.25 AMA PRA Category 1 Credits™, and up to 1.25 MOC Part II Self-Assessment credits. 

There are multiple biologics that have been approved for asthma. This session explores the patient profiles that may predict a response to each agent.

  • Anti-IgE
  • Anti-IL-5

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 1.25 credits as meeting the requirements for MOC Part II Self-Assessment.

The live activity was supported by an independent educational grant from GlaxoSmithKline

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Describe what biomarkers may be indicative of good response to treatment with anti-IgE.
  • Discuss differences in outcomes of pivotal trials for the two approved anti-IL5 agents.
  • Determine whether treatment failure with one biologic dictates lack of response to other agents.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2017 Annual Meeting is conveniently located online at disclosures

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Attendance
  • 1.25 MOC
Course opens: 
Course expires: 
  • John J. Oppenheimer, MD, FACAAI
  • Thomas B. Casale, MD, FACAAI
  • Paul O'Byrne, MD
  • Elliot Israel, MD

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Attendance
  • 1.25 MOC


Please login or create an account to take this course.